UK’s NICE Recommends Against Lynparza Tablets on NHS for Advanced, Platinum-sensitive Ovarian Cancers

UK’s NICE Recommends Against Lynparza Tablets on NHS for Advanced, Platinum-sensitive Ovarian Cancers
The U.K.’s National Institute of Health and Care Excellence (NICE) has decided not to recommend Lynparza (olaparib) tablets as maintenance treatment for women with relapsed ovarian cancer who respond to platinum-based chemotherapy due to unsatisfactory cost-effectiveness. However, this is not the advisory committee’s final guidance on the therapy, and its decision could be reversed following the ongoing

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *